MetaCap

Azora Therapeutics (AZR) vs Kazia Therapeutics (KZIA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kazia Therapeutics is the larger company by market cap ($56.2 million vs $55.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZR-24.51%KZIA-40.94%
+7%-18%-43%
Oct 28, 20261 yearNov 20, 2026
AZR+1.05%KZIA-42.12%
+10%-17%-45%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZR versus KZIA key metrics
MetricAZRKZIA
Share price$3.85$4.92
Market cap$55.00M$56.22M
1-day change-0.52%-8.38%
YTD return—-28.59%
1-year return—-41.08%
5-year return—-99.01%
EPS (TTM)$-18.09$-6.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.98M—
52-week high$8.25$17.40
52-week low$1.31$4.50
Distance from 52-week high-53.33%-71.72%
Analyst consensus—none
Avg. price target upside—+476.02%
Average volume50.12K307.30K
Shares outstanding14.29M11.43M
Employees—6
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kazia Therapeutics

KZIA stock →

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

AZR vs KZIA FAQ

Which is bigger, Azora Therapeutics or Kazia Therapeutics?

Kazia Therapeutics (KZIA) is larger, with a market capitalization of $56.22M compared with $55.00M for Azora Therapeutics (AZR).

Are Azora Therapeutics and Kazia Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons